JP2014519318A5 - - Google Patents

Download PDF

Info

Publication number
JP2014519318A5
JP2014519318A5 JP2014509819A JP2014509819A JP2014519318A5 JP 2014519318 A5 JP2014519318 A5 JP 2014519318A5 JP 2014509819 A JP2014509819 A JP 2014509819A JP 2014509819 A JP2014509819 A JP 2014509819A JP 2014519318 A5 JP2014519318 A5 JP 2014519318A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
antibody
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014509819A
Other languages
English (en)
Japanese (ja)
Other versions
JP6181043B2 (ja
JP2014519318A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2012/051004 external-priority patent/WO2012153123A1/en
Publication of JP2014519318A publication Critical patent/JP2014519318A/ja
Publication of JP2014519318A5 publication Critical patent/JP2014519318A5/ja
Application granted granted Critical
Publication of JP6181043B2 publication Critical patent/JP6181043B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014509819A 2011-05-06 2012-05-08 抗神経成長因子抗体ならびにそれを調製および使用する方法 Active JP6181043B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161483491P 2011-05-06 2011-05-06
US61/483,491 2011-05-06
US201161531439P 2011-09-06 2011-09-06
US61/531,439 2011-09-06
PCT/GB2012/051004 WO2012153123A1 (en) 2011-05-06 2012-05-08 Anti-nerve growth factor antibodies and methods of preparing and using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017075108A Division JP6526089B2 (ja) 2011-05-06 2017-04-05 抗神経成長因子抗体ならびにそれを調製および使用する方法

Publications (3)

Publication Number Publication Date
JP2014519318A JP2014519318A (ja) 2014-08-14
JP2014519318A5 true JP2014519318A5 (enExample) 2016-07-21
JP6181043B2 JP6181043B2 (ja) 2017-08-16

Family

ID=46168541

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014509819A Active JP6181043B2 (ja) 2011-05-06 2012-05-08 抗神経成長因子抗体ならびにそれを調製および使用する方法
JP2017075108A Active JP6526089B2 (ja) 2011-05-06 2017-04-05 抗神経成長因子抗体ならびにそれを調製および使用する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017075108A Active JP6526089B2 (ja) 2011-05-06 2017-04-05 抗神経成長因子抗体ならびにそれを調製および使用する方法

Country Status (14)

Country Link
US (2) US20140170136A1 (enExample)
EP (2) EP3502136A1 (enExample)
JP (2) JP6181043B2 (enExample)
KR (1) KR101833465B1 (enExample)
CN (1) CN103764677A (enExample)
AU (1) AU2012252153B2 (enExample)
BR (1) BR112013028652A8 (enExample)
CA (1) CA2834983C (enExample)
ES (1) ES2704007T3 (enExample)
GB (1) GB2504888B (enExample)
MY (1) MY160884A (enExample)
RU (1) RU2640252C2 (enExample)
SG (2) SG10201500957QA (enExample)
WO (1) WO2012153123A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
WO2012075340A2 (en) 2010-12-01 2012-06-07 Alderbio Holdings Llc Anti-ngf compositions and use thereof
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
AU2012252153B2 (en) * 2011-05-06 2016-07-07 Zoetis Services Llc Anti-nerve growth factor antibodies and methods of preparing and using the same
CA2932515C (en) 2013-12-20 2023-08-01 Intervet International B.V. Caninized antibodies
ES2853823T3 (es) 2014-09-30 2021-09-17 Intervet Int Bv Anticuerpos de PD-L1 que se unen a PD-L1 canino
CN104910274B (zh) * 2015-02-12 2018-05-04 北京华安科创生物技术有限公司 抗人神经生长因子的中和性单克隆抗体12c11及其杂交瘤细胞株
CN104774265B (zh) * 2015-02-12 2018-05-04 北京华安科创生物技术有限公司 抗人神经生长因子的中和性单克隆抗体11f1及其杂交瘤细胞株
BR112017025029A2 (pt) * 2015-05-22 2018-08-07 Astellas Pharma Inc. ?novo fragmento fab de anticorpo ngf anti- humano?.
JP7008020B2 (ja) 2015-12-18 2022-01-25 インターベット インターナショナル ベー. フェー. ヒトおよびイヌil-4rアルファに対するイヌ化ヒト抗体
US11091556B2 (en) 2015-12-18 2021-08-17 Intervet Inc. Caninized human antibodies to human IL-4R alpha
CN119390821A (zh) 2017-08-15 2025-02-07 伊兰科美国公司 兽药用IgG Fc变体
GB2578867A (en) * 2018-10-09 2020-06-03 Genome Res Ltd Animal models and therapeutic molecules
AU2019250128A1 (en) 2018-10-15 2020-04-30 Avent Inc. Compositions, systems, kits, and methods for neural ablation
CA3199234A1 (en) * 2020-10-22 2022-04-28 Scout Bio, Inc. Method of suppressing immune response to vector-delivered therapeutic protein
TW202306990A (zh) 2021-05-12 2023-02-16 大陸商江蘇恆瑞醫藥股份有限公司 特異性結合rankl和ngf的抗原結合分子及其醫藥用途
KR20240107201A (ko) 2021-08-31 2024-07-08 스카우트 바이오, 인코포레이티드 항원-결합 분자 및 이의 용도
WO2025036564A1 (de) * 2023-08-17 2025-02-20 Gottfried Wilhelm Leibniz Universität Hannover (Luh) Nukleinsäuresequenz, vektor, screening-verfahren und verfahren zur herstellung von rekombinanten antikörpern

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
AU632843B2 (en) * 1989-08-10 1993-01-14 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Cat-mouse heterohybridoma and gene fragment coding for constant region of feline immunoglobulin
WO1992022324A1 (en) 1991-06-14 1992-12-23 Xoma Corporation Microbially-produced antibody fragments and their conjugates
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
EP3372614B1 (en) * 2004-04-07 2022-06-08 Rinat Neuroscience Corp. Methods for treating bone cancer pain by administering a nerve growth factor antagonist
ITRM20050290A1 (it) * 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
US20070212703A1 (en) 2005-09-27 2007-09-13 Stemmer Willem P Proteinaceous pharmaceuticals and uses thereof
US8337842B2 (en) * 2008-09-04 2012-12-25 Vet Therapeutics, Inc. Monoclonal antibodies
US8435523B2 (en) 2009-05-04 2013-05-07 Abbott Research B.V. Antibodies against nerve growth factor (NGF) with enhanced in vivo stability
BR112012022342A2 (pt) * 2010-03-04 2017-02-14 Vet Therapeutics Inc anticorpos monoclonais dirigidos a cd52
JP5911813B2 (ja) * 2010-03-04 2016-04-27 ベット・セラピューティクス・インコーポレイテッドVet Therapeutics Inc. Cd20に対するモノクローナル抗体
CA2808577C (en) * 2010-08-19 2018-09-25 Abbott Laboratories Anti-ngf antibodies and their use
AU2012252153B2 (en) * 2011-05-06 2016-07-07 Zoetis Services Llc Anti-nerve growth factor antibodies and methods of preparing and using the same

Similar Documents

Publication Publication Date Title
JP2014519318A5 (enExample)
JP2014519317A5 (enExample)
CN110191896B (zh) 改进的血清白蛋白结合物
JP7254699B2 (ja) 抗bcma重鎖のみ抗体
IL305912B1 (en) Improved serum albumin binders
EA201991099A1 (ru) Антитела против cd73 и их применение
JP2019147801A5 (enExample)
EA202091590A1 (ru) Антитела против pd-l1 и варианты их применения
JP2018506277A5 (enExample)
JP2014522236A5 (enExample)
JP2013538057A5 (enExample)
JP2019535763A5 (enExample)
JP2018527919A5 (enExample)
JP2010526028A5 (enExample)
RU2018113505A (ru) Il-8-связывающие антитела и их применения
JP2016188209A5 (enExample)
RU2015143886A (ru) Антитела к тау и способы применения
RU2016100892A (ru) Антитела против tweakr и их применение
JP2016512551A5 (enExample)
RU2016137256A (ru) АНТИТЕЛА К ФАКТОРУ КОМПЛЕМЕНТА Bb
JP2019506841A5 (enExample)
RU2016129113A (ru) Антитела к pd-1 собак
JP2017522903A5 (enExample)
TR201817932T4 (en) ANTIBODIES THAT BIND STAPHYLOCOCCUS AUREUS ALPHA TOXIN SPECIFICALLY AND METHODS OF USE
JP2014526898A5 (enExample)